NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Source: PRnewswire
Merger Approval: NLS Pharmaceutics Ltd. shareholders have approved the merger with Kadimastem Ltd., clearing the final corporate hurdle for the formation of NewCelX Ltd.
Future Plans: The combined company is set to be listed on Nasdaq under the ticker "NCEL," pending final approval, marking a significant step in establishing a transatlantic biopharma leader.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
